Mesoblast

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.

Strong Operational Progress and Continued Growth in Revenues from Royalties Strong Operational Progress and Continued Growth in Revenues from Royalties

Mesoblast Reports 2019 Full Year Results

NEW YORK and MELBOURNE, Australia, Aug.  27, 2019  (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, will host a webcast to discuss the financial results for the period ending June 30, 2019.

Mesoblast to Host Analyst Call on 2019 Financial Results for Year and Fourth Quarter Ended June 30, 2019

Primary Endpoint of Confirmatory Trial to be Reduction in Major Mucosal Bleeding Events Primary Endpoint of Confirmatory Trial to be Reduction in Major Mucosal Bleeding Events

FDA Provides Guidance on Clinical Pathway to Marketing Application for Revascor in End-Stage Heart Failure Patients With an LVAD

New Gold

Teva Pharmaceutical

Find out how a combination of factors helped these stocks defy a down market.

Why Teva Pharmaceutical Industries, Mesoblast, and New Gold Jumped Today

Mesoblast Limited product rexlemestrocel-L has received Orphan Drug Destination from the U.S. Food and Drug Administration for prevention of gastrointestinal bleeding in patients with left ventricular assist device.

Mesoblast Trades Higher After Heart Failure Cell Therapy Receives Orphan Drug Status

Mesoblast's (MESO) CEO Silviu Itescu on Q3 2019 Results - Earnings Call Transcript

Acorda Therapeutics

Incyte

Repligen

Mesoblast (MESO) begins the rolling submission of a BLA for its lead product, candidate remestemcel-L, to the FDA for treating children with steroid-refractory acute graft versus host disease.

Mesoblast Starts Rolling BLA Submission for Remestemcel-L

News for Mesoblast Stock (MESO)